{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:22:39Z","timestamp":1764829359245,"version":"3.46.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the long-term prognosis of the fellow-eye in patients with age-related macular degeneration (AMD) who underwent pars plana vitrectomy (PPV) with submacular tissue plasminogen activator injection (SM-tPA) for significant submacular hemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective single-center cohort study including all consecutive patients who underwent PPV with SM-tPA for AMD-related submacular hemorrhage (SMH) between 2010 and 2022, with a minimum follow-up of 2 years. Data was collected from electronic medical records and included demographic characteristics, visual acuity, optical coherence tomography findings, adverse events, further ocular diagnoses in the fellow-eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-seven patients (57% male; mean age 80 years) were included, with a mean follow-up of 82 months. At baseline, most patients had AMD in the fellow-eye (62% dry-AMD; 30% wet-AMD). During follow-up, AMD progressed in 64% of the patients who did not have wet-AMD in their fellow eye at the time of presentation. Seven patients (15%) experienced SMH in the fellow-eye within 1 month to 5 years after initial surgery.<\/jats:p>\n                    <jats:p>\n                      The mean VA of the fellow-eye at presentation was 0.64 LogMAR, with a nonsignificant improvement in the first two years. Subsequently, a statistically significant VA deterioration was observed (final mean VA 0.8 LogMAR,\n                      <jats:italic>p<\/jats:italic>\n                      =0.009). By the final follow-up, 30% of patients had better VA in the operated eye, and 26% were legally blind in the fellow-eye.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients treated with SM-tPA are at high risk for AMD progression and vision loss in the fellow-eye. Close monitoring of the fellow eye is warranted, and treatment decisions for the involved eye should not be based solely on good fellow-eye vision, given the long-term risk of deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-06944-0","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:50:29Z","timestamp":1755755429000},"page":"3113-3119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poor long-term fellow-eye outcomes after vitrectomy with subretinal tissue plasminogen activator for AMD-related submacular hemorrhage"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-222X","authenticated-orcid":false,"given":"Shalev","family":"Fried","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofri","family":"Vorobichik Berar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattan","family":"Arazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar","family":"Klain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal Yaakov","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Fogel Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Platner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avner","family":"Hostovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"6944_CR1","doi-asserted-by":"publisher","first-page":"e1569","DOI":"10.1111\/AOS.15137","volume":"100","author":"PH Gabrielle","year":"2022","unstructured":"Gabrielle PH, Maitrias S, Nguyen V et al (2022) Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry. Acta Ophthalmol 100:e1569\u2013e1578. https:\/\/doi.org\/10.1111\/AOS.15137","journal-title":"Acta Ophthalmol"},{"key":"6944_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/JCM13020367","author":"F Confalonieri","year":"2024","unstructured":"Confalonieri F, Ferraro V, Barone G et al (2024) Outcomes in the treatment of subretinal macular hemorrhage secondary to age-related macular degeneration: a systematic review. J Clin Med. https:\/\/doi.org\/10.3390\/JCM13020367","journal-title":"J Clin Med"},{"key":"6944_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000027400","volume":"213","author":"A Scupola","year":"1999","unstructured":"Scupola A, Coscas G, Soubrane G, Balestrazzi E (1999) Natural history of macular subretinal hemorrhage in Age-Related macular degeneration. Ophthalmologica 213:97\u2013102. https:\/\/doi.org\/10.1159\/000027400","journal-title":"Ophthalmologica"},{"key":"6944_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","volume":"16","author":"RL Avery","year":"1996","unstructured":"Avery RL, Fekrat S, Hawkins BS, Bressler NM (1996) Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16:183\u2013189. https:\/\/doi.org\/10.1097\/00006982-199616030-00001","journal-title":"Retina"},{"key":"6944_CR5","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.2147\/OPTH.S324091","volume":"15","author":"D Iannetta","year":"2021","unstructured":"Iannetta D, De Maria M, Bolletta E et al (2021) Subretinal injection of recombinant tissue plasminogen activator and gas tamponade to displace acute submacular haemorrhages secondary to age-related macular degeneration. Clin Ophthalmol 3649\u20133659. https:\/\/doi.org\/10.2147\/OPTH.S324091","journal-title":"Clin Ophthalmol"},{"key":"6944_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0161-6420(01)00648-0","volume":"108","author":"LO Hattenbach","year":"2001","unstructured":"Hattenbach LO, Klais C, Koch FHJ, G\u00fcmbel HOC (2001) Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 108:1485\u20131492. https:\/\/doi.org\/10.1016\/S0161-6420(01)00648-0","journal-title":"Ophthalmology"},{"key":"6944_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000534440","volume":"246","author":"D Oncel","year":"2023","unstructured":"Oncel D, Oncel D, Mishra K et al (2023) Current management of subretinal hemorrhage in neovascular Age-Related macular degeneration. Ophthalmologica 246:295\u2013305. https:\/\/doi.org\/10.1159\/000534440","journal-title":"Ophthalmologica"},{"key":"6944_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ophtha.2023.04.014","volume":"130","author":"PH Gabrielle","year":"2023","unstructured":"Gabrielle PH, Delyfer MN, Glacet-Bernard A et al (2023) Surgery, tissue plasminogen activator, antiangiogenic agents, and Age-Related macular degeneration study: A randomized controlled trial for submacular hemorrhage secondary to Age-Related macular degeneration. Ophthalmology 130:947\u2013957. https:\/\/doi.org\/10.1016\/j.ophtha.2023.04.014","journal-title":"Ophthalmology"},{"key":"6944_CR9","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/J.OPHTHA.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST et al (2020) Age-Related macular degeneration preferred practice Pattern\u00ae. Ophthalmology 127:P1\u2013P65. https:\/\/doi.org\/10.1016\/J.OPHTHA.2019.09.024","journal-title":"Ophthalmology"},{"key":"6944_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/JCM9103088","volume":"9","author":"S Jeong","year":"2020","unstructured":"Jeong S, Park DG, Sagong M (2020) Management of a submacular hemorrhage secondary to age-related macular degeneration: a comparison of three treatment modalities. J Clin Med 9:1\u201310. https:\/\/doi.org\/10.3390\/JCM9103088","journal-title":"J Clin Med"},{"key":"6944_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/S12886-022-02639-W","author":"D Patikulsila","year":"2022","unstructured":"Patikulsila D, Winaikosol P, Choovuthayakorn J et al (2022) Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series. BMC Ophthalmol. https:\/\/doi.org\/10.1186\/S12886-022-02639-W","journal-title":"BMC Ophthalmol"},{"key":"6944_CR12","doi-asserted-by":"publisher","unstructured":"Ali Said Y, Dewilde E, Stalmans P, Oishi A (2021) Visual Outcome after Vitrectomy with Subretinal tPA Injection to Treat Submacular Hemorrhage Secondary to Age-Related Macular Degeneration or Macroaneurysm. J Ophthalmol 2021:. https:\/\/doi.org\/10.1155\/2021\/3160963","DOI":"10.1155\/2021\/3160963"},{"key":"6944_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/J.JCJO.2017.10.010","volume":"53","author":"VR Juncal","year":"2018","unstructured":"Juncal VR, Hanout M, Altomare F et al (2018) Surgical management of submacular hemorrhage: experience at an academic Canadian centre. Can J Ophthalmol 53:408\u2013414. https:\/\/doi.org\/10.1016\/J.JCJO.2017.10.010","journal-title":"Can J Ophthalmol"},{"key":"6944_CR14","doi-asserted-by":"publisher","unstructured":"Ogata M, Oh H, Nakata A et al (2022) Displacement of submacular hemorrhage secondary to age-related macular degeneration with subretinal injection of air and tissue plasminogen activator. Sci Rep 2022 12:1 12:1\u201311. https:\/\/doi.org\/10.1038\/s41598-022-26289-6","DOI":"10.1038\/s41598-022-26289-6"},{"key":"6944_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/J.OPHTHA.2003.10.020","volume":"111","author":"S Olivier","year":"2004","unstructured":"Olivier S, Chow DR, Packo KH et al (2004) Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology 111:1201\u20131208. https:\/\/doi.org\/10.1016\/J.OPHTHA.2003.10.020","journal-title":"Ophthalmology"},{"key":"6944_CR16","doi-asserted-by":"publisher","first-page":"2050313X2097033","DOI":"10.1177\/2050313X20970337","volume":"8","author":"A Karamitsos","year":"2020","unstructured":"Karamitsos A, Papastavrou V, Ivanova T et al (2020) Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series. SAGE Open Med Case Rep 8:2050313X2097033. https:\/\/doi.org\/10.1177\/2050313X20970337","journal-title":"SAGE Open Med Case Rep"},{"key":"6944_CR17","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1097\/IAE.0B013E318287D99D","volume":"33","author":"M Fujikawa","year":"2013","unstructured":"Fujikawa M, Sawada O, Miyake T et al (2013) Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina 33:1908\u20131914. https:\/\/doi.org\/10.1097\/IAE.0B013E318287D99D","journal-title":"Retina"},{"key":"6944_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/J.ORET.2017.07.012","volume":"2","author":"S Sharma","year":"2018","unstructured":"Sharma S, Kumar JB, Kim JE et al (2018) Pneumatic displacement of submacular hemorrhage with subretinal air and tissue plasminogen activator: initial united States experience. Ophthalmol Retina 2:180\u2013186. https:\/\/doi.org\/10.1016\/J.ORET.2017.07.012","journal-title":"Ophthalmol Retina"},{"key":"6944_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/J.AJO.2013.01.012","volume":"155","author":"G Shienbaum","year":"2013","unstructured":"Shienbaum G, Garcia Filho CAA, Flynn HW et al (2013) Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol 155:1009\u20131013. https:\/\/doi.org\/10.1016\/J.AJO.2013.01.012","journal-title":"Am J Ophthalmol"},{"key":"6944_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-023-32874-0","author":"M Maruyama-Inoue","year":"2023","unstructured":"Maruyama-Inoue M, Kitajima Y, Yanagi Y et al (2023) Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-023-32874-0","journal-title":"Sci Rep"},{"key":"6944_CR21","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/IAE.0000000000003885","volume":"43","author":"M Miki","year":"2023","unstructured":"Miki M, Miyata M, Ooto S et al (2023) Predictors of 3-month and 1-year visual outcomes after vitrectomy with subretinal tissue plasminogen activator injection for submacular hemorrhage. Retina 43:1971\u20131979. https:\/\/doi.org\/10.1097\/IAE.0000000000003885","journal-title":"Retina"},{"key":"6944_CR22","doi-asserted-by":"publisher","unstructured":"Group SST (SST) R (2004) Surgery for Hemorrhagic Choroidal Neovascular Lesions of Age-Related Macular Degeneration: Ophthalmic Findings: SST Report No. 13. Ophthalmology 111:1993. https:\/\/doi.org\/10.1016\/J.OPHTHA.2004.07.023","DOI":"10.1016\/J.OPHTHA.2004.07.023"},{"key":"6944_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231202048\/ASSET\/IMAGES\/LARGE\/10.1177_11206721231202048-FIG2.JPEG","author":"E Barayev","year":"2023","unstructured":"Barayev E, Tiosano A, Zlatkin R et al (2023) Prognostic factors for visual acuity improvement after treatment of submacular hemorrhage secondary to exudative age-related macular degeneration. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721231202048\/ASSET\/IMAGES\/LARGE\/10.1177_11206721231202048-FIG2.JPEG","journal-title":"Eur J Ophthalmol"},{"key":"6944_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.5301\/EJO.5000500","volume":"24","author":"E Moisseiev","year":"2014","unstructured":"Moisseiev E, Ami T, Ben, Barak A (2014) Vitrectomy and subretinal injection of tissue plasminogen activator for large submacular hemorrhage secondary to AMD. Eur J Ophthalmol 24:925\u2013931. https:\/\/doi.org\/10.5301\/EJO.5000500","journal-title":"Eur J Ophthalmol"},{"key":"6944_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0271447","author":"N Inoue","year":"2022","unstructured":"Inoue N, Kato A, Araki T et al (2022) Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: a retrospective multicenter survey. PLoS One. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0271447","journal-title":"PLoS One"},{"key":"6944_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/S00417-010-1483-X\/TABLES\/5","volume":"249","author":"SS Mann","year":"2011","unstructured":"Mann SS, Rutishauser-Arnold Y, Peto T et al (2011) The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). Graefe\u2019s Archive Clin Experimental Ophthalmol 249:209\u2013214. https:\/\/doi.org\/10.1007\/S00417-010-1483-X\/TABLES\/5","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"key":"6944_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","volume":"123","author":"RB Bhisitkul","year":"2016","unstructured":"Bhisitkul RB, Desai SJ, Boyer DS et al (2016) Fellow eye comparisons for 7-Year outcomes in Ranibizumab-Treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology 123:1269\u20131277. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.033","journal-title":"Ophthalmology"},{"key":"6944_CR28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/JAMAOPHTHALMOL.2019.1947","volume":"137","author":"R Parikh","year":"2019","unstructured":"Parikh R, Avery RL, Saroj N et al (2019) Incidence of new choroidal neovascularization in fellow eyes of patients with Age-Related macular degeneration treated with intravitreal Aflibercept or Ranibizumab. JAMA Ophthalmol 137:914\u2013920. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2019.1947","journal-title":"JAMA Ophthalmol"},{"key":"6944_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00417-024-06605-8","volume":"263","author":"E Sadeghi","year":"2025","unstructured":"Sadeghi E, Vupparaboina SC, Bollepalli SC et al (2025) Incidence and risk factors of fellow-eyes wet conversion in unilateral neovascular age-related macular degeneration over 15-year follow-up. Graefes Arch Clin Exp Ophthalmol 263:77\u201386. https:\/\/doi.org\/10.1007\/s00417-024-06605-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6944_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/J.ORET.2023.03.016","volume":"7","author":"O Trivizki","year":"2023","unstructured":"Trivizki O, Wang L, Shi Y et al (2023) Symmetry of macular fundus features in age-related macular degeneration. Ophthalmol Retina 7:672\u2013682. https:\/\/doi.org\/10.1016\/J.ORET.2023.03.016","journal-title":"Ophthalmol Retina"},{"key":"6944_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13063-021-05966-3","volume":"23","author":"TL Jackson","year":"2022","unstructured":"Jackson TL, Bunce C, Desai R et al (2022) Vitrectomy, subretinal tissue plasminogen activator and intravitreal gas for submacular haemorrhage secondary to exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. Trials 23:99. https:\/\/doi.org\/10.1186\/s13063-021-05966-3","journal-title":"Trials"},{"key":"6944_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41433-019-0719-1","volume":"34","author":"JC van Meurs","year":"2020","unstructured":"van Meurs JC (2020) Many ways to displace a blood clot. But do we need to do so? Eye (Lond) 34:997\u2013998. https:\/\/doi.org\/10.1038\/s41433-019-0719-1","journal-title":"Eye (Lond)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06944-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:50:57Z","timestamp":1764820257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06944-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6944"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06944-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Sheba Medical Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by the IRB due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No conflicting relationship exists for any autor.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}